Last reviewed · How we verify
RSP-1502
At a glance
| Generic name | RSP-1502 |
|---|---|
| Sponsor | Respirion Pharmaceuticals Pty Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSP-1502 CI brief — competitive landscape report
- RSP-1502 updates RSS · CI watch RSS
- Respirion Pharmaceuticals Pty Ltd portfolio CI